Interní Med. 2009; 11(6): 276-281

Ulcerative colitis - classification, diagnosis, therapy and quality of life

MUDr. Libor Gabalec
Interní oddělení - gastroenterologie, Orlickoústecká nemocnice a.s

Etiology and pathogenesis of ulcerative colitis is still unknown. It is a result of a combination of environmental, genetic and immunological

factors in which an uncontrolled immune response within the intestinal lumen leeds to inflammation. Defect of innate immune response

to microbial agents is involved in ulcerative colitis. Induction and maintenance of remission, mucosal healing, the avoidance of surgical

intervention and decreasing the likelyhood of cancer developing are the primary therapeutic goals in ulcerative colitis.

Keywords: ulcerative colitis (UC), inflammatory bowel disease (IBD), quality of life.

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gabalec L. Ulcerative colitis - classification, diagnosis, therapy and quality of life. Interní Med. 2009;11(6):276-281.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55 (6): 749-753. Go to original source... Go to PubMed...
    2. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55 Suppl 1: 1-15. Go to original source... Go to PubMed...
    3. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369 (9573): 1627-1640. Go to original source... Go to PubMed...
    4. Koutroubakis IE, Vlachonikolis IG. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol 2000; 95 (1): 171-176. Go to original source... Go to PubMed...
    5. McGilligan VE, Wallace JM, Heavey PM, Ridley DL, Rowland IR. Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis. Inflamm Bowel Dis 2007; 13 (1): 108-115. Go to original source... Go to PubMed...
    6. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. J Gastroenterol 2006; 12 (30): 4819-4831. Go to original source...
    7. Mařatka Z. Gastroenterologie. Univerzita Karlova, Praha 1999.
    8. Slanař O, Bortlík M, Buzková H, Donoval R, Pechandová K, Šebesta I et al. Polymorphisms of the TPMT gene in the Czech healthy population and patients with inflammatory bowel disease. Nucleosides Nucleotides Nucleic Acids 2008; 27 (6): 835-838. Go to original source... Go to PubMed...
    9. Lukáš M. et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. Čes a Slov Gastroent a Hepatol 62 (5): 285-291.
    10. Červený P, Bortlík M, Kuběna A, Vlček J, Lakatos PL, Lukáš M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13 (10): 1244-1249. Go to original source... Go to PubMed...
    11. Kruis W, Frič P, Pokrotnieks J, Lukáš M, Fixa B, Kaščák M et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53 (11): 1617-1623. Go to original source... Go to PubMed...
    12. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48 (4): 526-535. Go to original source... Go to PubMed...
    13. Lukáš M. Idiopatické střevní záněty a kolorektální karcinom. Nové souvislosti a další perspektivy. Čes a Slov Gastroent a Hepatol 2006 60 (3): 113-118.
    14. Papa A, Danese S, Gasbarrini A, Gasbarrini G. Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14 (11): 1403-1409. Go to original source... Go to PubMed...
    15. Papa A, Danese S, Grillo A, Gasbarrini G, Gasbarrini A. Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 2003; 98 (6): 1247-1251. Go to original source... Go to PubMed...
    16. Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2002; 97 (8): 1994-1999. Go to original source... Go to PubMed...
    17. Irvine EJ. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 2008; 14 (4): 554-565. Go to original source... Go to PubMed...
    18. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007; 76 (9): 1323-1330. Go to PubMed...
    19. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55 (Suppl 1): 16-35. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.